Veeva Systems vs Vir Biotechnology Inc. Common Stock — how do they compare? Veeva Systems trades at $298.35 (market cap $48.84B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.76B). The key difference: Veeva Systems is far larger — about 27.8× Vir Biotechnology Inc. Common Stock's market cap, and Veeva Systems is trading nearer its 52-week high, Vir Biotechnology Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Veeva Systems for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| VEEV | VIR | |
|---|---|---|
Market Cap | $48.84B | $1.76B |
Volume | 2,253,175 | 2,764,948 |
Sector | Technology | Health |
52-Week High | $301.63 | $11.78 |
52-Week Low | $151.43 | $5.12 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $41.75B | $1.32B |
Signals from Pluang's Aura AI — not financial advice
Veeva Systems (VEEV) trades at $301.63, up 1.95% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 74.96% gross margins and consistent earnings beats, while expanding partnerships with IQVIA and Servier enhance growth prospects. Recent news highlights AI innovations and increasing adoption among biotech firms, supporting positive sentiment.
Outlook remains favorable with analyst consensus at Buy (67% rating) and $290.50 price target, though valuation multiples appear elevated. Key risks include market saturation concerns and potential volatility from RSI overbought signals. The stock's proximity to 52-week highs suggests continued investor confidence in Veeva's life sciences software leadership.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →